Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Basilea Pharmaceutic (BPMUF)

Basilea Pharmaceutic (BPMUF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 598,969
  • Shares Outstanding, K 10,740
  • Annual Sales, $ 135,250 K
  • Annual Income, $ -22,490 K
  • 60-Month Beta 1.60
  • Price/Sales 4.03
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/30/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.7800 +9.83%
on 06/29/20
55.7700 unch
on 07/08/20
+3.1700 (+6.03%)
since 06/05/20
3-Month
49.6000 +12.44%
on 05/22/20
55.7700 unch
on 07/08/20
+4.8500 (+9.52%)
since 04/07/20
52-Week
36.5900 +52.42%
on 08/19/19
60.0500 -7.13%
on 01/15/20
+19.0600 (+51.92%)
since 06/13/19

Most Recent Stories

More News
Basilea reports strong financial results for half-year 2020, progress in R&D portfolio and successful completion of strategic projects, despite COVID-19

- Financial results reflecting strong Cresemba and Zevtera performance and continued focus on expense management

BPMUF : 55.7700 (+9.83%)
Basilea reports acceptance for regulatory review of Pfizer's marketing authorization application for antifungal isavuconazole (Cresemba(R)) in China

Basel, Switzerland, August 07, 2020

BPMUF : 55.7700 (+9.83%)
Basilea announces completion of its transaction involving a partial repurchase of its existing bond and the issuance of a new bond

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

BPMUF : 55.7700 (+9.83%)
Basilea announces data presentations at ESMO Virtual Congress 2020

Basel, Switzerland, July 28, 2020

BPMUF : 55.7700 (+9.83%)
Basilea announces a conversion price of CHF 62.50 for its New Bonds and the acceptance of tendered Bonds in an aggregated principal amount of approximately CHF 47 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

BPMUF : 55.7700 (+9.83%)
Basilea announces completion of patient enrolment into first cohort of phase 2 study FIDES-01 with derazantinib in bile duct cancer (iCCA)

Basel, Switzerland, July 20, 2020

BPMUF : 55.7700 (+9.83%)
Basilea continues with the implementation of the Repurchase Offer and the issuance of New Bonds

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

BPMUF : 55.7700 (+9.83%)
Basilea Bonds tendered in an aggregate principal amount of approximately CHF 47 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

BPMUF : 55.7700 (+9.83%)
Basilea reports the launch of antifungal Cresemba(R) (isavuconazole) in Taiwan, triggering the second milestone payment related to Asia-Pacific

Basel, Switzerland, July 15, 2020

BPMUF : 55.7700 (+9.83%)
Basilea announces partial repurchase offer for at least CHF 90 million and up to CHF 110 million in principal amount of its outstanding convertible bonds due 2022

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

BPMUF : 55.7700 (+9.83%)
Trade BPMUF with:

Key Turning Points

2nd Resistance Point 55.7700
1st Resistance Point 55.7700
Last Price 55.7700
1st Support Level 55.7700
2nd Support Level 55.7700

See More

52-Week High 60.0500
Last Price 55.7700
Fibonacci 61.8% 51.0883
Fibonacci 50% 48.3200
Fibonacci 38.2% 45.5517
52-Week Low 36.5900

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar